Evidence map›Paper›PMID 28811304›Full record

Trial reportBlood2017

Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow.

Vasilios A Morikis, Shannon Chase, Ted Wun, Elliot L Chaikof, John L Magnani, Scott I Simon

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Sialyl LewisACS medicinal chemistry letters · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Psoriatic Neutrophils Are Primed in Circulation for Enhanced βThe Journal of investigative dermatology · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Vasilios A MorikisDepartment of Biomedical Engineering, University of California Davis, Davis, CA.
Shannon ChaseDepartment of Biomedical Engineering, University of California Davis, Davis, CA.
Ted WunDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA.
Elliot L ChaikofDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and.
John L MagnaniGlycoMimetics, Inc., Gaithersburg, MD.
Scott I SimonDepartment of Biomedical Engineering, University of California Davis, Davis, CA.ORCID 0000-0003-1186-6611
University of California, Davis · USBeth Israel Deaconess Medical Center · USGlycoMimetics (United States) · USVA Northern California Health Care System · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
Outside-in Mechanotransduced Inflammatory TargetsR01AI047294 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI SIMON, SCOTT IRWIN · 1999 to 2021
$7.0M
Animal Models of Infectious Diseases Training ProgramT32AI060555 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI MCSORLEY, STEPHEN J · 2004 to 2025
$3.3M
Facile Synthesis of Glycosulfopeptides and Related BioconjugatesU01GM116196 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHAIKOF, ELLIOT, CUMMINGS, RICHARD D · 2015 to 2018
$2.6M
A PSGL-1 Glycopeptide Mimetic for Treatment of Metabolic SyndromeR01DK107405 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHAIKOF, ELLIOT, KAHN, BARBARA B. · 2016 to 2019
$2.5M
A PSGL-1 Glycopeptide Mimetic for Treatment of Venous ThromboembolismR01HL128237 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHAIKOF, ELLIOT · 2015 to 2018
$1.7M
NCATS NIH HHS UL1 TR001860NHLBI NIH HHS R01 HL128237NIAID NIH HHS R01 AI047294NIAID NIH HHS T32 AI060555NIDDK NIH HHS R01 DK107405NIGMS NIH HHS U01 GM116196
6 · The paper itself

Abstract

E-selectin extends from the plasma membrane of inflamed endothelium and serves to capture leukocytes from flowing blood via long-lived catch-bonds that support slow leukocyte rolling under shear stress. Its ligands are glycosylated with the tetrasaccharide sialyl Lewis

Indexed as

Cell Migration InhibitionLeukocyte RollingMechanotransduction, CellularTransendothelial and Transepithelial MigrationAdultAnemia, Sickle CellATP-Binding Cassette TransportersCalgranulin BCD18 AntigensCell AdhesionEndothelium, VascularE-SelectinFemaleHumansL-SelectinMaleABCC11 protein, humanATP-Binding Cassette TransportersCalgranulin BCD18 AntigensE-SelectinL-SelectinOligosaccharidesSialyl Lewis X AntigenTLR4 protein, humanToll-Like Receptor 4

Identifiers

PMID28811304
PMCPMC5680610
OpenAlexW2749596444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.